Medifolin

Calcium Folinate, the active ingredient in Medifolin, is a folate analog presented as an oral formulation for oral use. It is employed to mitigate toxicity from certain chemotherapy agents and to supplement folate in deficiency states. It is commonly used in oncology protocols and in patients requiring folate repletion before or after antifolate therapy.

GNH USA supplies Medifolin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Calcium Folinate is used in clinical settings that involve antifolate chemotherapy or folate deficiency. - Methotrexate toxicity rescue: reduces high‑dose methotrexate‑induced bone marrow and renal toxicity. - 5‑Fluorouracil modulation: enhances the anticancer effect of 5‑FU in colorectal and head‑neck cancers. - Folate deficiency supplementation: restores normal folate levels in patients with folate‑deficient states.

Calcium Folinate may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes. - Diarrhea: loose stools. - Transient rash: mild skin irritation. - Elevated liver enzymes: mild hepatic enzyme rise. - Fever: low‑grade temperature increase.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hepatic dysfunction: marked increase in transaminases or jaundice. - Neutropenia: significant reduction in white blood cells. - Thromboembolic events: rare clot formation. - Renal failure: acute kidney injury in predisposed patients. - Hypersensitivity syndrome: multi‑system allergic response.

When prescribing Calcium Folinate, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: monitor kidney function and adjust therapy as needed. - Hepatic dysfunction: assess liver enzymes before and during treatment. - Pregnancy and lactation: evaluate risk‑benefit ratio and consult obstetric guidance. - Concomitant antifolates: avoid simultaneous use that may diminish rescue effect. - Known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep in original container, protect from moisture and light.

Calcium Folinate can interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid): - Pemetrexed: concurrent use may increase toxicity and reduce rescue efficacy. - High‑dose methotrexate without appropriate timing: may negate protective effect. - Anticoagulants (warfarin): folate may alter INR, requiring close monitoring.

Moderate Interactions (Monitor Closely): - 5‑Fluorouracil: may enhance cytotoxicity, necessitate dose adjustment. - Cytarabine: potential additive myelosuppression. - Trimethoprim‑sulfamethoxazole: may increase risk of bone marrow suppression.